ArticleJournal of Alzheimer's disease reports
Persistence with antidementia therapy in Germany: A retrospective cohort study of 567,815 patients.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the availability of these therapies, maintaining long-term adherence remains a significant challenge. Objective: This retrospective cohort study aimed to investigate 12-month and 5-year persistence with antidementia drug therapy in Germany and to examine the association between demographic and clinical variables and the risk of therapy discontinuation. Methods: Patients aged 60 years or older from the IQVIA Longitudinal Prescription Database who received an initial prescription for antidementia therapy between 2016 and 2023 (index date) were included. Time to discontinuation was estimated using the Kaplan-Meier method, and a multivariable Cox proportional hazards model was used to assess associations between predefined variables and the risk of discontinuation. Results: The study included 567,815 patients (mean age: 80.2 years, 59.1% female). Five years after the index date, 19.8% of dementia patients were still receiving therapy, with a 12-month persistence rate of 53.1%. Cox regression models conducted for the total population revealed that younger age (<70 versus ≥90 years; HR: 1.21; 95% CI: 1.19-1.23; 71-80 years versus ≥90 years; HR: 1.13; 95% CI: 1.11-1.14) was significantly associated with an increased risk of therapy discontinuation. Initiating therapy with memantine was associated with a slightly lower risk of discontinuation compared to donepezil (HR: 0.87; 95% CI: 0.86-0.87). Conclusion: In this study, half of the patients discontinued antidementia therapy within one year and 80% within five years. Younger age was linked to a higher risk of therapy discontinuation, while memantine therapy was associated with improved persistence, potentially reflecting better adherence among patients with more advanced dementia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.